Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Abstract
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non–small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is...
Paper Details
Title
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Published Date
Feb 16, 2017
Volume
376
Issue
7
Pages
629 - 640
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History